Summary
- Profile Type
- Technology offer
- POD Reference
- TOFR20250514008
- Term of Validity
- 14 May 2025 - 14 May 2026
- Company's Country
- France
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The French company provides an intelligent solution that analyses customers' specific needs to offer them the optimum method of data de-identification, whether pseudonymisation, anonymisation or synthetic data, thus ensuring secure and compliant management of sensitive information. Commercial agreements are sought.
- Full Description
-
The French company offers an independent and autonomous solution. It is operated in SaaS mode, guaranteeing isolation and multi-tenancy and it provides all the functional components to ensure its execution. The solution is hosted on the French company infrastructure in compliance with the HDS (Healthcare Data Hosting) security standard and complies with the API recommendations made by the CNIL in 2023 (cf https://www.cnil.fr/sites/cnil/files/2023-07/recommandation_api.pdf).
Its functional architecture comprises three main blocks:
1. The data acquisition interface provides support for users of the solution. It enables data to be securely retrieved from the platform thanks to the capabilities of the connectors implemented. The data transmitted by the user can take various formats (data content, metadata, data model, etc.).
2. The data process interfaces have been developed within the platform to retrieve and process the raw input data.
3. The data delivery interface allows, once the data have been successfully delivered, to securely deleted all residual content and data. For audit and alert purposes, the activities of each stage are recorded externally.
Platform users log on securely to the platform via dual identification. Once they have logged on to the tool, they can open:
The Documentation' tab to:
• Consult technical and legal documentation ;
The ‘Workspace' tab to:
• Find out which identification method is best for their project using questionnaire ;
• Import structured data (CSV type, etc.) onto the platform in a workspace ;
• Apply the 3 de-identification methods to their data: pseudonymisation, anonymisation and/or synthetic data ;
• View and compare the 3 methods using statistics on data security and quality ;
• Download their de-identified data ;
The product is aimed primarily at players in the field of health research who need to process personal health data (DSCP – Données de Santé à Caractère Personnel in French). According to the CNIL (Commission Nationale de l'Informatique et des Libertés), personal health data is data relating to the past, present or future physical or mental health of a natural person that reveals information about that person's state of health.
With this innovative solution, health professionals can quickly identify and test the optimal de-identification method for their project, then generate and obtain the new data using the chosen method. The study can then begin straight away, avoiding lengthy regulatory processes or even the search for an actor to generate the de-identified data. Also, the plateform can be used by research students who often don't have the time or opportunity to access DSCP. Using it, they can use raw data to obtain a set of de-identified data, increase it to a larger set and start analysing it. Finally, healthcare manufacturers may be interested in sharing their data. The DGA publication encourages the sharing and exchange of data. In this case, this solution is the intermediary tool for pre-processing the data between the holder (the manufacturer) and the future user, to obtain a set of de-identified data that can be exchanged rapidly.
Users and beneficiaries of the solution are one and the same. In most cases, it will be used directly by the beneficiaries. However, it is possible to distinguish between direct and indirect beneficiaries:
- The direct beneficiaries are the secondary users of the data. Indeed, they will use the tool as a benefit for them in order to help them in their research work thanks to the de-identification and enhancement of their data ;
- Healthcare professionals and patients are indirect beneficiaries of this solution. This solution accelerates medical research and innovation, enabling healthcare professionals to make new medical advances and treat more patients.
In addition, the solution serves the public interest by helping healthcare professionals to advance medical innovation. Commercial agreements are sought. - Advantages and Innovations
-
This solution is an innovative tool for advanced de-identification and privacy protection. It is the first tool that allows researchers to compare and test de-identification methods on their own dataset and choose the most optimal one for their research project. It relieves them of the pre-processing stages of their data so that they can concentrate on their core business. Depending on their needs, it enables them to:
• Offer documentation ;
• Define the most optimal de-identification method for their project between pseudonymisation, anonymisation and synthetic data by a questionnaire ;
• Import and process multiple formats ;
• Generate pseudonimised, anonymised data and synthetic data with Artificial Intelligence ;
• View and test de-identification results on own data ;
• Determine the best de-identification method via the results obtained ;
• Analyse and process the de-identified data ;
• Generate the chosen de-identification method on all its data.
The solution benefits research centres attached to health establishments or private and/or public research centres. Research centres using DSCP are constrained by numerous legal procedures leading to technical questions/installations such as a compliant and secure framework for processing and the choice of de-identification methods. These issues can be a brake on progress in their research and an impediment to innovation. Thanks to it, healthcare establishments could benefit more quickly from medical innovations and succeed in treating a greater number of patients with new solutions. It offers many benefits:
• Rapid access to good-quality, up-to-date information on legal and technical concepts
• To provide customers with a compliant and secure framework
• Centralise information and platforms by offering a tool capable of generating data following any de-identification process
• Enable customers to focus on their core business
• Save time and energy on the sometimes lengthy regulatory procedures. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 12: Responsible Consumption and Production
- Goal 6: Clean Water and Sanitation
- Goal 7: Affordable and Clean Energy
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
- Any healthcare entity requiring this technology is a good match. Could be a SME, a big company as well as a research center and a university.
- Type and Size of Partner
- SME <=10
- SME 11-49
- SME 50 - 249
- Big company
- R&D Institution
- University
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001002 - Clinical Research, Trials
- 06001001 - Biostatistics, Epidemiology
- 06001005 - Diagnostics, Diagnosis
- 06003001 - Bioinformatics
- Market keywords
- 02003 - Specialised Turnkey Systems
- 02006004 - Data processing, analysis and input services
- 02006009 - Other computer services
- 01004008 - Other data communications
- Sector Groups Involved
- Health
- Targeted countries
- All countries